Inte:Ligand
Private Company
Total funding raised: $5.8M
Overview
Inte:Ligand is a long-established, private Austrian company specializing in computer-aided drug design (CADD) software and services. Its flagship product, LigandScout, is a well-cited platform for structure- and ligand-based pharmacophore modeling, virtual screening, and molecular docking, aimed at improving early-stage discovery efficiency. The company operates a hybrid business model, generating revenue through software licensing and expert consulting services for clients worldwide, positioning itself as a technology enabler rather than a drug developer.
Technology Platform
LigandScout software suite for pharmacophore-based virtual screening and molecular docking, integrated with AI/ML technologies. Includes ilib diverse for virtual library generation.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Operates in a crowded field with competitors ranging from large software vendors (e.g., Dassault Systèmes BIOVIA, Schrödinger) to specialized CADD/AI startups (e.g., Atomwise, BenevolentAI). Differentiation is based on deep expertise in pharmacophore modeling, user-friendly interface, and a hybrid software-plus-services model.